Engineered NK cells take on tough cancers in first human test
Disease control
Not yet recruiting
This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that hel…
Phase: EARLY_PHASE1 • Sponsor: Genovn Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC